CJC-1295 Ipamorelin dosage: what was administered in the studies

Read this first

This page is a record of what researchers gave to which species, by which route — not advice for any person. There is no established human dose for CJC-1295 Ipamorelin, because the fixed blend has never been studied in a controlled human trial. What exists are doses from single-compound studies: human pharmacokinetic doses for the CJC-1295 half, and mostly rodent doses for the ipamorelin half. The two halves also run on completely different clocks — CJC-1295 with DAC lasts days, ipamorelin lasts hours, and the no-DAC CJC-1295 form lasts about thirty minutes. Below, every figure is logged as "studied at X in species Y by route Z." Nothing here is a protocol, a starting point, or a recommendation, and no figure should be read as one.

Cjc 1295 ipamorelin dosage: the doses studied

CJC-1295 (with DAC). Human Phase 1 pharmacokinetic studies administered 30 to 90 µg/kg subcutaneously ^[1][8]. In GHRH-knockout mice, once-daily CJC-1295 at 2 µg normalized body weight, length, lean mass and subcutaneous fat — direct in-vivo proof of functional GHRH-receptor agonism, but a mouse dose, not a human one ^[9].

CJC-1295 no-DAC (Mod GRF 1-29). This short, pulsatile GHRH signal has no formal standalone human pharmacokinetic study; it is modeled in research protocols on the order of roughly 100 to 200 µg per injection. The detail belongs on the mod grf 1-29 page.

Ipamorelin. Rodent studies used roughly 100 µg/kg three times daily for bone outcomes, 0.5 mg/kg/day for bone-mineral measures, and 0.01 to 1 mg/kg intravenously for gut-motility work; about 1 µg/kg plateaued the GH response in rodent models. No validated human dose is published.

These are observed research values, attributed to their species and route. They are recorded here because they appear in the literature — not because they translate to a person.

Half-lives and timing

The half-life gap is the whole story of this pairing's pharmacology. CJC-1295 with DAC has a human half-life of roughly six to eight days — it is albumin-bound, and the peptide is detectable in rat plasma beyond 72 hours ^[1][5]. CJC-1295 no-DAC (Mod GRF 1-29) is on the order of minutes to about thirty minutes, like native GHRH, because the enzyme DPP-IV (dipeptidyl peptidase-IV, which clips GHRH at its N-terminus) cleaves it rapidly — the very degradation that CJC-1295's amino-acid substitutions and DAC were engineered to resist ^[11]. Ipamorelin is under about two hours in rodent plasma, with the peak GH response near forty minutes post-dose; no validated human half-life is published. Pairing a multi-day agent with an hours-long one is precisely why the net GH exposure of any given protocol is uncharacterized.

Routes and handling, in research context

Routes studied across the two compounds include subcutaneous, intravenous, continuous subcutaneous infusion via osmotic minipump in rodent models, and intranasal in ipamorelin's rodent pharmacokinetic work ^[12]. As a handling note — laboratory context only — lyophilized (freeze-dried) peptide is stable frozen for extended periods; once reconstituted with bacteriostatic water (sterile water with 0.9% benzyl alcohol as a preservative), aqueous peptide solutions are kept refrigerated at 2–8 °C and degrade over weeks via asparagine deamidation, and degradation products can be markedly less potent. Agitation and repeated freeze-thaw are avoided. None of this is an instruction to prepare or administer anything; it is the standard storage chemistry recorded in the literature.